Iterative Health combines centralized operations, expert staffing, proprietary AI technology, and clinical trial expertise to operate a multispecialty clinical research network that embeds research into routine care. Its global network includes more than 100 research sites across North America, Europe, India, and Australia and partnerships with over 40 pharmaceutical, biotech, medical device, and CRO organizations. The company reports delivering 2x faster site activation for IBD trials and 3x higher patient enrollment rates compared to industry benchmarks, with an average of more than two IBD patients randomized every business day across the network. Iterative Health's model centers on site success to improve trial execution reliability at scale. The company plans to expand beyond gastroenterology and hepatology into cardiology and obesity while continuing geographic expansion and broader provider partnerships. Iterative Health is headquartered in Cambridge, Massachusetts and New York, New York.

Total raised

$77M

Funding rounds

1

Latest round

Series C

Latest activity

Apr 2026